Mark Roschewski, Senior Clinician at National Cancer Institute (NCI), shared on X:
“Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology
Read this paper which shows that ctDNA MRD by PhasED-Seq is the most precise way to define a remission after therapy for LBCL.”
Title: Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma
Authors: Mark Roschewski, David M. Kurtz, Jason R. Westin, Ryan C. Lynch, Ajay K. Gopal, Stefan K. Alig, Brian J. Sworder, Hua-Jay J. Cherng, Christian Kuffer, Derek Blair, Krystal Brown, Jordan S. Goldstein, Andre Schultz, Sandra Close, Jacob J. Chabon, Maximilian Diehn, Wyndham H. Wilson, Ash A. Alizadeh
More posts featuring Large B-cell Lymphoma.